↓ Skip to main content

Dove Medical Press

Article Metrics

Cognitive effects of a dietary supplement made from extract of Bacopa monnieri, astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: a noncomparative…

Overview of attention for article published in Neuropsychiatric Disease and Treatment, February 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page
reddit
1 Redditor

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
78 Mendeley
Title
Cognitive effects of a dietary supplement made from extract of Bacopa monnieri, astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: a noncomparative, exploratory clinical study
Published in
Neuropsychiatric Disease and Treatment, February 2014
DOI 10.2147/ndt.s51092
Pubmed ID
Authors

Danilo Zanotta, Silvana Puricelli, Guido Bonoldi

Abstract

A prospective cohort, noncomparative, multicenter trial was conducted to explore the potential of a phytotherapeutic compound, available as a dietary supplement and containing extracts of Bacopa monnieri and Haematococcus pluvialis (astaxanthin) plus phosphatidylserine and vitamin E, in improving cognition in subjects diagnosed with mild cognitive impairment. Enrolled subjects (n=104) were aged 71.2±9.9 years and had a mini-mental state examination score of 26.0±2.0 (mean ± standard deviation). They underwent the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) test and the clock drawing test at baseline and upon completion of a 60-day period of dietary supplementation with one tablet daily of the tested compound. In 102 assessable subjects, total ADAS-cog scores improved from 13.7±5.8 at baseline to 9.7±4.9 on day 60, and the clock drawing test scores improved from 8.5±2.3 to 9.1±1.9. Both changes were statistically significant (P<0.001). Memory tasks were the individual components of ADAS-cog showing the largest improvements. In a multivariate analysis, larger improvements in total ADAS-cog score were associated with less compromised baseline mini-mental state examination scores. Perceived efficacy was rated as excellent or good by 62% of study subjects. The tested compound was well tolerated; one nonserious adverse event was reported in the overall study population, and perceived tolerability was rated excellent or good by 99% of the subjects. In conclusion, dietary supplementation with the tested compound shows potential for counteracting cognitive impairment in subjects with mild cognitive impairment and warrants further investigation in adequately controlled, longer-term studies.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
India 1 1%
Netherlands 1 1%
United States 1 1%
Unknown 74 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 20 26%
Student > Bachelor 11 14%
Other 10 13%
Student > Master 9 12%
Student > Ph. D. Student 9 12%
Other 12 15%
Unknown 7 9%
Readers by discipline Count As %
Medicine and Dentistry 23 29%
Agricultural and Biological Sciences 15 19%
Psychology 10 13%
Neuroscience 6 8%
Biochemistry, Genetics and Molecular Biology 3 4%
Other 13 17%
Unknown 8 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2014.
All research outputs
#9,814,370
of 15,430,898 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,474
of 2,527 outputs
Outputs of similar age
#137,564
of 255,840 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#56
of 96 outputs
Altmetric has tracked 15,430,898 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,527 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 255,840 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 96 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.